U.S. FDA Grants Lipogems(R) Second IDE Approval for a Clinical Trial on the Treatment for Knee OA

ATLANTA, Oct. 4, 2023 -- (Healthcare Sales & Marketing Network) -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA)... Devices, Orthopaedic, FDA Lipogems, MicroFat, knee osteoarthritis, osteoarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news